Frequently Asked Questions

Bakuchiol is a naturally occurring meroterpene phenol extracted from the seeds of Psoralea corylifolia (Babchi plant). It is widely recognised as the premier natural retinol alternative in cosmetics — delivering clinically comparable anti-ageing efficacy without the typical irritation associated with retinoids.

The INCI name is Bakuchiol. The CAS registry number is 10309-37-2. It is a C18 terpenoid phenol, chemically known as (1R,2E,6E,10E)-1-ethenyl-1,4,4-trimethyl-2,6,10-dodecatrien-12-ol.

Bakuchiol activates the same retinoid receptors (RAR and RXR) as retinol and retinoic acid, stimulating collagen synthesis, accelerating cell turnover, and regulating gene expression associated with skin ageing — all through a distinct molecular structure that bypasses the irritation pathways triggered by classical retinoids.

Bakuchiol provides multiple scientifically supported skin benefits: (1) Collagen and elastin stimulation for reduced fine lines and wrinkles, (2) Accelerated skin cell renewal, (3) Anti-inflammatory activity that calms acne-prone skin, (4) Antioxidant protection against oxidative stress, (5) Improved skin tone and radiance, and (6) Barrier strengthening and improved skin texture.

Yes. This is one of Bakuchiol's major advantages over retinol. Bakuchiol does not cause the redness, peeling, dryness, or photosensitivity commonly associated with retinol use. Multiple clinical studies have demonstrated its tolerability in sensitive skin types, including during pregnancy (unlike retinol, which is contraindicated in pregnancy — however, always consult a physician).

Published clinical studies have demonstrated that Bakuchiol at 0.5% performs comparably to 0.5% retinol for reducing fine lines, wrinkles, and hyperpigmentation — with significantly lower rates of facial skin irritation, stinging, and scaling. Bakuchiol also offers the advantage of photostability, making it suitable for daytime use.

Yes. Unlike retinol, Bakuchiol is photostable and does not degrade under UV exposure or sensitise the skin to sunlight. This makes it suitable for both morning and evening skincare formulations, significantly broadening its application scope versus retinol.

Yes. Bakuchiol is plant-derived from Psoralea corylifolia seeds and is considered vegan. It is biodegradable and is increasingly favoured by brands seeking clean-label, plant-based retinol alternatives for their skincare ranges.

Bakuchiol is typically used at concentrations of 0.5% to 2.0% in finished formulations. The efficacy-proven benchmark in clinical literature is 0.5%, though higher concentrations (up to 2%) may be used in targeted treatments such as serums, eye creams, and night creams.

Bakunova offers Bakuchiol in five advanced delivery formats: (1) Liposomal Bakuchiol — for controlled release and deep dermal penetration; (2) Bakuchiol Microemulsion — for transparent, elegant cosmetic aesthetics; (3) Bakuchiol Beta-CD Complex — for improved aqueous solubility; (4) Bakuchiol Solid Lipid Nanoparticles (SLN) — for sustained release and oxidative stability; (5) Bakuchiol Ionic Liquid (CAGE) — for maximum transdermal penetration.

Bakuchiol modulates inflammatory pathways including downregulation of pro-inflammatory cytokines and inhibition of sebaceous gland hyperactivity. Clinical studies have demonstrated a reduction in acne lesions comparable to retinol, making Bakuchiol a well-tolerated active for acne-prone and combination skin types.

Rosmarinic Acid is a naturally occurring polyphenol ester of caffeic acid and 3,4-dihydroxyphenyllactic acid. It is found at high concentrations in rosemary (Rosmarinus officinalis), sage, basil, and other Lamiaceae family plants. In cosmetics, it is prized for its exceptional antioxidant, anti-inflammatory, and skin-brightening properties.

The INCI name is Rosmarinic Acid. The CAS registry number is 20283-92-5. Its molecular formula is C₁₈H₁₆O₈ with a molecular weight of 360.31 g/mol. It is a phenolic acid with a characteristic deep yellow-brown colour.

Rosmarinic Acid offers four key biological activities in skin care: (1) Antioxidant & Oxidative Stress Protection — neutralising reactive oxygen species and free radicals; (2) Inflammatory Balance & Skin Comfort — calming stressed and reactive skin; (3) Skin Barrier & Protective Support — strengthening the skin's natural defence; (4) Tone Uniformity & Radiance Support — addressing oxidative-stress-linked pigmentation and dullness.

Rosmarinic Acid is primarily extracted from rosemary (Rosmarinus officinalis) and sage (Salvia officinalis), both members of the Lamiaceae family. These herbs have been used for centuries in traditional medicine for their antioxidant and antimicrobial properties, and modern cosmetic science has validated the efficacy of their key phenolic constituent.

Rosmarinic Acid scavenges free radicals and reactive oxygen species (ROS) through its multiple hydroxyl groups on the catechol and caffeic acid moieties. It also inhibits lipid peroxidation, chelates transition metal ions, and modulates enzymatic antioxidant systems (e.g., superoxide dismutase, catalase), providing multi-layered oxidative stress protection.

Yes. Rosmarinic Acid's anti-inflammatory activity — including inhibition of COX enzymes and modulation of NF-κB inflammatory signalling — makes it particularly beneficial for sensitive, rosacea-prone, or reactive skin types. It calms redness, reduces skin discomfort, and supports the skin's natural comfort responses without irritation.

Rosmarinic Acid is highly versatile and suited for: serums, essences, toners (aqueous formulations), antioxidant moisturisers, eye creams targeting dark circles, brightening treatments, sensitive skin soothing products, and post-procedure care formulations. Its water-soluble nature makes it ideal for water-phase formulations.

Yes. Rosmarinic Acid works synergistically with many other actives. It pairs well with Vitamin C (enhancing antioxidant capacity), niacinamide (for combined brightening), hyaluronic acid (in hydrating serums), ceramides (for barrier support), and peptides (anti-ageing serums). It is compatible with most cosmetic ingredients at recommended usage levels.

Bakunova offers Rosmarinic Acid in five advanced delivery systems: (1) Liposomal Rosmarinic Acid — enhanced dermal penetration and controlled release; (2) Rosmarinic Acid Microemulsion — transparent, water-compatible system; (3) Rosmarinic Acid Beta-CD Complex — improved aqueous solubility and photo-stability; (4) Rosmarinic Acid Solid Lipid Nanoparticles — prolonged release and oxidative stability; (5) Rosmarinic Acid Ionic Liquid (CAGE) — maximum transdermal delivery.

Hydroxypinacolone Retinoate (HPR) is a next-generation retinoid ester — a direct ester of retinoic acid conjugated to pinacolone. Unlike retinol which requires enzymatic conversion in the skin, HPR binds directly to retinoid receptors (RAR), delivering retinol-like efficacy without the irritation associated with conventional retinoids. Its INCI name is Hydroxypinacolone Retinoate.

HPR has CAS number 893412-73-2, molecular formula C₂₆H₃₈O₄, and molecular weight of 418.58 g/mol. It is classified as a retinoid ester and is considered a cosmetic-grade retinoid (not a pharmaceutical drug), making it available for use in over-the-counter skincare formulations in most markets.

Key differences: (1) Conversion pathway — Retinol must be converted to retinaldehyde then to retinoic acid in the skin; HPR is a direct retinoic acid ester that bypasses this multi-step conversion; (2) Tolerability — HPR causes significantly less irritation, redness, and peeling than retinol; (3) Stability — HPR is more stable in formulations; (4) Daytime use — HPR is photostable and can be used in daytime formulas; (5) Regulatory status — HPR is cosmetic-grade, avoiding pharmaceutical restrictions that apply to retinoic acid.

HPR delivers four key skin benefits: (1) Anti-Aging & Skin Renewal — directly activates retinoid receptors to stimulate collagen/elastin synthesis and accelerate cell turnover; (2) Retinol-Like Efficacy with Superior Tolerability — comparable pathway activation with significantly reduced irritation; (3) Pigmentation & Tone Uniformity — modulates melanin synthesis for brighter, more even skin tone; (4) Sebum Regulation & Acne Control — regulates sebaceous gland activity and supports pore refinement.

Yes. HPR is widely used as an entry point into retinoid skincare for sensitive skin types or retinoid-naive consumers who have not previously used retinol. Its reduced irritation profile means it can typically be tolerated by skin types that cannot tolerate retinol. It is also a preferred option for formulators developing retinoid-active products for markets where retinoic acid is restricted.

HPR is considered more photostable than retinol, and many formulators incorporate it in daytime serums and moisturisers. However, as a general best practice, SPF protection should always be recommended when using any retinoid-active product during the day, and formulation stability should be verified with appropriate photo-stability testing.

Bakunova provides HPR in five advanced delivery systems: (1) Liposomal HPR — controlled release, deep dermal penetration; (2) HPR Microemulsion — transparent, elegant formulation aesthetics; (3) HPR Beta-CD Complex — improved aqueous solubility and photo-stability; (4) HPR Solid Lipid Nanoparticles — sustained release, oxidative stability, extended shelf life; (5) HPR Ionic Liquid (CAGE) — maximum transdermal penetration without conventional solvents.

HPR combines well with many cosmetic actives. It is commonly formulated with peptides (synergistic anti-ageing), niacinamide (tone uniformity), hyaluronic acid (hydration), antioxidants such as Vitamin C and Rosmarinic Acid (complementary oxidative protection), and ceramides (barrier support). As with all retinoids, formulators should assess compatibility and stability with specific co-actives. Avoid high-concentration AHA/BHA combinations without appropriate pH management.

HPR is typically used at concentrations of 0.05% to 0.5% in finished formulations. Lower concentrations (0.05–0.1%) are suitable for daily-use products with broad consumer targeting. Higher concentrations (0.2–0.5%) are appropriate for targeted anti-ageing treatments and professional-grade serums where higher retinoid activity is desired.

Cosmetic actives often face significant challenges in their native form: poor skin penetration, chemical instability, unfavourable solubility, rapid degradation, and short shelf life. Advanced delivery technologies address all these limitations — improving bioavailability, extending stability, enabling controlled release, and ensuring actives reach their target site in the skin at effective concentrations.

Liposomal encapsulation involves surrounding an active ingredient within phospholipid bilayers — structures that closely mimic the skin's own cell membranes. The resulting vesicles (liposomes) are typically 50–200 nm in size. Because the bilayer is biomimetic, liposomes fuse with skin cells and release their payload intracellularly, enabling deep dermal penetration, controlled release, and enhanced bioavailability. Liposomes can carry both hydrophilic and lipophilic actives.

A microemulsion is a thermodynamically stable, optically transparent (or translucent) system of water, oil, and surfactant where the active is solubilised in nano-scale droplets (typically 10–100 nm). Unlike conventional emulsions, microemulsions are self-assembling and extremely stable. Key advantages include: transparent/clear aesthetic suitable for serums and essences, excellent solubilisation of lipophilic actives, superior skin penetration due to nano-droplet size, and long-term physical stability.

β-Cyclodextrin (Beta-CD) is a cyclic oligosaccharide with a hydrophilic exterior and a hydrophobic interior cavity. When an active molecule is enclosed within this cavity, it forms an inclusion complex. This dramatically improves the aqueous solubility and dissolution rate of poorly water-soluble actives, enhances photo-stability (protecting light-sensitive molecules), masks odour, and improves formulation compatibility. Beta-CD complexes are particularly valuable for retinoids and polyphenols in water-based formulations.

Solid Lipid Nanoparticles (SLN) are colloidal particles (typically 50–500 nm) made from solid lipids — lipids that remain solid at room and body temperature. The active ingredient is incorporated within the solid lipid matrix. SLNs provide prolonged sustained release (the solid matrix slows diffusion), exceptional oxidative stability (the lipid matrix protects sensitive actives), and improved shelf life. They are preferred for delivering unstable actives like retinoids and polyphenols that need protection from oxidation.

CAGE stands for Choline And Geranic acid — an ionic liquid formed from the combination of choline (a naturally occurring quaternary ammonium compound) and geranic acid (a naturally occurring terpene acid). The CAGE ionic liquid disrupts the skin's tight junction barrier transiently, enabling unprecedented transdermal delivery of active ingredients without using conventional organic solvents. This technology is particularly effective for delivering larger molecules or hydrophilic actives that typically have limited skin penetration.

The CAGE Ionic Liquid technology provides the maximum transdermal penetration — enabling delivery beyond the stratum corneum into the viable epidermis and dermis. For targeted dermal delivery, liposomal systems are excellent due to their biomimetic bilayer structures. Microemulsions also offer enhanced penetration versus bulk formulations. The optimal choice depends on the target skin layer, the active's physicochemical properties, and the desired release profile.

Encapsulated actives significantly outperform their raw counterparts in several ways: (1) Enhanced skin penetration — delivery systems physically transport the active into deeper skin layers; (2) Controlled release — sustained activity over longer periods vs. burst release; (3) Improved stability — protection from oxidation, light, and pH extremes; (4) Better bioavailability — more active reaches its target site; (5) Improved tolerance — encapsulation can reduce local irritation of actives such as retinoids; (6) Extended shelf life — protection from environmental degradation.

Yes. Bakunova's encapsulated active systems are designed as formulation-ready ingredients that can be added directly to formulations at the appropriate phase (typically the cool-down phase below 40°C or the water phase, depending on the system). Each product comes with full technical guidance including recommended use levels, incorporation instructions, compatibility notes, and suggested formulation types. Our technical team is available to assist with any formulation questions.

Many of Bakunova's delivery systems use naturally derived or nature-identical ingredients in their carrier systems. Liposomal systems typically use phospholipids derived from soy or sunflower lecithin. The CAGE Ionic Liquid system uses naturally occurring choline and geranic acid. However, specific compatibility with certified organic or Ecocert standards should be verified on a case-by-case basis — contact our technical team for detailed information.

For each product, Bakunova provides: Certificate of Analysis (CoA), Technical Data Sheet (TDS) with physicochemical properties and usage guidelines, Safety Data Sheet (SDS/MSDS), Stability data, Suggested formulation examples, and Compatibility notes. Additional regulatory support documentation can be provided upon request for specific markets.

Bakunova has an in-house development pipeline of 5 innovative dermatology programs (BN-001 to BN-005), developed using our proprietary combination of premium active ingredients and advanced delivery technologies. These programs target unmet needs in Vitiligo, Acne, Psoriasis, Skin Whitening, and Anti-Aging. All programs have successfully completed preclinical development and are now available for out-licensing and co-development partnerships.

The five pipeline programs address the following dermatological conditions: BN-001 — Vitiligo; BN-002 — Acne; BN-003 — Psoriasis; BN-004 — Skin Whitening; BN-005 — Anti-Aging. These represent significant market opportunities in both the prescription dermatology and OTC cosmeceutical segments.

All five Bakunova pipeline programs (BN-001 through BN-005) have successfully completed preclinical development. This includes in-vitro efficacy studies, mechanism of action characterisation, formulation development, and preclinical safety assessment. The programs are now available for licensing to partners who will advance them through clinical development.

Preclinical Completed means that a program has successfully passed all pre-human development stages, including: in-vitro efficacy validation, mechanism of action studies using cell-based or biochemical assays, formulation feasibility and optimisation, and initial safety/toxicology profiling. The program is ready for IND (Investigational New Drug) enabling studies and first-in-human clinical trials with a development partner.

Bakunova offers four types of licensing and partnership structures: (1) Out-Licensing — full rights transfer to a development partner; (2) Co-Development — joint development with shared costs, risks, and upside; (3) Regional Rights — geography-specific licensing for specific markets; (4) Global Commercialization — worldwide development and commercialisation partnerships. Each program can be structured differently depending on partner needs.

Bakunova's in-house development platform combines premium active ingredients with advanced delivery technologies to create differentiated, efficacious, and safe dermatology products. This means pipeline programs benefit from both best-in-class active compounds and optimised delivery systems that enhance penetration, stability, and target site concentration — creating a meaningful competitive moat versus conventional formulations.

Interested companies can initiate a partnership discussion by contacting Bakunova directly at info@srdkbiochem.com or reaching out to Drug Discovery Labs (our North American partner) at bpandi@drugdiscoverylabs.com. Please provide a brief introduction of your company, the program(s) of interest, and the type of partnership structure you are considering. We will arrange an introductory call with our business development team.

Sample requests can be made by: (1) Using the Contact Us form on our website and selecting 'Sample Request' as the subject; (2) Emailing info@srdkbiochem.com (India) or bpandi@drugdiscoverylabs.com (USA/North America); (3) Calling +91 7661898368 (India) or +1 (919) 389-9258 (USA). Please specify the product name, format (e.g., Liposomal Bakuchiol), and your intended application. Our team will respond within 24–48 hours.

To process your sample request efficiently, please provide: (1) Company name and your role; (2) Specific product(s) of interest and the delivery format; (3) Your application/formulation type (e.g., serum, moisturiser, eye cream); (4) Target use concentration; (5) Shipping address and any import requirements. This allows our technical team to provide the most relevant sample and accompanying technical support.

Yes. Bakunova ships products internationally from our Hyderabad, India facility. For customers in North America, Drug Discovery Labs (our marketing partner) can facilitate domestic supply and logistics within the USA. For specific import/export requirements, documentation needs, or customs considerations, please discuss these with our team during the inquiry process.

Standard sample lead times are 5–10 business days from confirmation of request and receipt of relevant documentation (e.g., company details for compliance purposes). For customers in North America, Drug Discovery Labs may be able to facilitate faster local delivery. Commercial order lead times vary by product and volume — contact our team for specific timelines.

Yes. Bakunova provides formulation technical support as part of our customer partnership approach. Our technical team can advise on: recommended use levels, incorporation guidelines, compatibility with other ingredients, suggested formulation types, pH and temperature stability, and troubleshooting formulation challenges. We aim to be a true technical partner, not just a supplier.

Standard documentation provided with all Bakunova products includes: Certificate of Analysis (CoA) with batch-specific results, Technical Data Sheet (TDS) with full physicochemical characterisation, Safety Data Sheet (SDS / MSDS), INCI declaration, Country of Origin documentation, and shelf-life / stability information. Additional documentation for specific regulatory markets (EU Cosmetics Regulation, FDA, etc.) can be provided upon request.

Yes. Bakunova has the R&D capability to develop custom encapsulation and delivery technology solutions for customer-specified active ingredients. This can include liposomal, microemulsion, cyclodextrin complexation, SLN, or ionic liquid formulations for actives beyond our current standard portfolio. Custom development projects are discussed on a case-by-case basis with clearly defined timelines, deliverables, and IP arrangements.

Bakunova's primary model is B2B supply of cosmetic active ingredients and delivery technology solutions to brands and formulators who incorporate them into their own finished products. For specific private label or white-label enquiries, please contact our team to discuss your requirements and explore how we can collaborate.

To stay informed about new product launches, pipeline updates, and technical insights from Bakunova, you can: (1) Contact us to join our B2B mailing list; (2) Connect with us on LinkedIn; (3) Reach out to Drug Discovery Labs for North American updates. We periodically publish technical content, product bulletins, and industry updates for our registered partners.

Minimum order quantities vary by product type and delivery format. For standard actives (e.g., bulk Bakuchiol, Rosmarinic Acid, HPR), MOQs apply based on production lot sizes. For encapsulated delivery systems (Liposomal, Microemulsion, SLN, etc.), MOQs may differ due to the manufacturing process. Please contact our sales team directly at info@srdkbiochem.com for current MOQ information and pricing specific to your requirements.

Pricing and payment terms are established through direct discussion with our sales team and depend on factors including product type, order volume, delivery format, destination, and partnership structure. To receive a quotation, please contact us at info@srdkbiochem.com with your product interests and approximate quantities. For North American inquiries, contact Drug Discovery Labs at bpandi@drugdiscoverylabs.com.